Legal & General Group
NXTC icon

Legal & General Group’s NextCure NXTC Stock Holding History

Legal & General Group’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-200
Closed -$24K – 3600
2021
Q1 		$24K Sell
200
-13
-6% -$1.88K ﹤0.01% 3057
2020
Q4 		$28K Hold
213
– – ﹤0.01% 2966
2020
Q3 		$23K Sell
213
-54
-20% -$6.64K ﹤0.01% 2938
2020
Q2 		$68K Buy
267
+72
+37% +$27.4K ﹤0.01% 2637
2020
Q1 		$86K Sell
195
-46
-19% -$24.6K ﹤0.01% 2453
2019
Q4 		$155K Buy
241
+194
+413% +$97.3K ﹤0.01% 2461
2019
Q3 		$17K Hold
47
– – ﹤0.01% 3183
2019
Q2 		$8K Buy
+47
New +$9.77K ﹤0.01% 3394

Other funds holding NXTC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Legal & General Group's NXTC Position: Q2 2021 in Review

Legal & General Group sold out of NextCure (NXTC) in Q2 2021, closing a stake of 200 shares — an estimated $24K sold.

Legal & General Group first reported a position in NXTC in Q2 2019 and held it in 8 quarters. The position peaked at $155K in Q4 2019. 78 funds tracked by Wall St. Rank hold NXTC as of Q2 2021.

  • Legal & General Group reported no remaining NextCure position as of Q2 2021 after selling out during the quarter.
  • Legal & General Group sold 200 NextCure shares in Q2 2021, an estimated $24K.
  • Legal & General Group first reported a position in NextCure in Q2 2019 and held it in 8 quarters.
  • Legal & General Group's NextCure position peaked at $155K in Q4 2019.
  • 78 funds tracked by Wall St. Rank held NextCure as of Q2 2021.

Based on Legal & General Group's 13F filing for Q2 2021, filed 12 Aug 2021.